Literature DB >> 25598153

Successful treatment of kaposiform lymphangiomatosis with sirolimus.

Zuopeng Wang1, Kai Li1, Wei Yao1, Kuiran Dong1, Xianmin Xiao1, Shan Zheng1.   

Abstract

Generalized lymphatic anomaly (GLA) is a rare and often fatal congenital lymphatic disorder that also commonly affects bone. Kaposiform lymphangiomatosis (KLA) is a novel subtype of GLA with poor prognosis and no proper treatment guidelines. A 9-year-old male with recurrent pleural effusion was clinically diagnosed as KLA. Following sirolimus therapy at a dose of 0.8 mg/m(2) twice daily, pleural effusion was significantly decreased and the general status of the patient markedly improved. The clinical course indicates that sirolimus may present an effective therapeutic option in KLA. Moreover, KLA should be considered in differential diagnosis for cases of GLA with coagulopathy.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  generalized lymphatic anomaly; kaposiform lymphangiomatosis; sirolimus; vascular malformation

Mesh:

Substances:

Year:  2015        PMID: 25598153     DOI: 10.1002/pbc.25422

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

Review 1.  Advances in the Medical Management of Vascular Anomalies.

Authors:  Kiersten W Ricci
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

2.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

3.  Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.

Authors:  Peter Baluk; Li-Chin Yao; Julio C Flores; Dongwon Choi; Young-Kwon Hong; Donald M McDonald
Journal:  JCI Insight       Date:  2017-08-17

4.  Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

Authors:  Guy Chowers; Gadi Abebe-Campino; Hana Golan; Asaf Vivante; Shoshana Greenberger; Michalle Soudack; Galia Barkai; Ilana Fox-Fisher; Dong Li; Michael March; Mark R Battig; Hakon Hakonarson; Denise Adams; Yoav Dori; Adi Dagan
Journal:  Pediatr Res       Date:  2022-03-04       Impact factor: 3.953

5.  Sirolimus in the treatment of kaposiform lymphangiomatosis.

Authors:  Jiangyuan Zhou; Kaiying Yang; Siyuan Chen; Yi Ji
Journal:  Orphanet J Rare Dis       Date:  2021-06-08       Impact factor: 4.123

Review 6.  Cystic angiomatosis, a heterogeneous condition: Four new cases and a literature review.

Authors:  Aurélie Najm; Elise Soltner-Neel; Benoît Le Goff; Pascale Guillot; Yves Maugars; Jean-Marie Berthelot
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

7.  Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.

Authors:  Naoki Sakata; So-Ichi Suenobu; Munehiro Okano; Satoshi Ueda; Masatomo Kimura; Tsukasa Takemura
Journal:  Rare Tumors       Date:  2018-05-30

8.  Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

Authors:  Yi Ji; Siyuan Chen; Suhua Peng; Chunchao Xia; Li Li
Journal:  Orphanet J Rare Dis       Date:  2019-07-05       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.